Sign up
Pharma Capital

Daré Bioscience looks to do for women what Viagra did for men

SST-6007 is the second product in Daré’s growing portfolio of novel therapeutic candidates that address unmet needs in women’s reproductive and sexual health
A couple making love
No pharmacologic options have yet been FDA-approved for Female Sexual Arousal Disorder

Daré Bioscience Inc (NASDAQ:DARE) is to license SST-6007, a potential treatment for female sexual arousal disorder (FSAD), from Strategic Science & Technologies.

FSAD is characterised mainly by an inability to attain or maintain sufficient physical sexual arousal, thus causing distress or interpersonal difficulty.  

SST-6007 is a sildenafil citrate cream that is applied to the skin; sildenafil is the same active ingredient found in Viagra, the treatment that has put a spring in the step of many a man.

The SST-6007 proprietary cream formulation is specifically designed to locally increase blood flow to the vulvar-vaginal tissue in women, leading to a potential improvement in genital arousal response and overall sexual experience.

Approval required

If approved, Daré believes SST-6007 would be the first treatment for FSAD approved by the Food & Drug Administration.

“We look forward to working closely with SST to bring SST-6007 to the market for women, leveraging SST’s deep knowledge of FSAD and our experience developing innovative women’s health products and readying them for US commercialization,” said Sabrina Martucci Johnson, the president and chief executive officer of Daré Bioscience.

“We are confident that SST-6007 has the potential to significantly impact women with Female Sexual Arousal Disorder, an area that has long been studied but for which there are currently no FDA approved treatments,” she added.

Shares shot up by almost half to US$2.77 on news of the collaboration agreement.

John-H.jpg


Register here to be notified of future DARE Company articles
View full DARE profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.